Gary,
The tone of your response was both refreshing, and inciteful. (hard to come by on SNRS message boards)
What do you think about this:
Sunrise Technologies International (SNRS) Quarterly Earnings Conference Call
C. Russell Trenary III, President/CEO
March 1, Duration 45 minutes
cheetahmail.com
President/CEO C. Russell Trenary III of Sunrise Technologies International discusses Q4 results, the pending approval of a
new treatment for hyperopia (farsightedness), and a recent executive-level appointment at the company.
Sunrise Technologies, which produces and markets high-tech eye care treatment procedures, announced a year-end net loss of
$26,145,000 on Dec. 31, 1999 compared with a net loss of $17,821,000 for the same 1998 period. The company, however, has
since raised $11.7 million.
On Jan. 13, the Ophthalmic Devices Panel unanimously voted to recommend FDA approval of Sunrise?s Hyperion LTK (laser
thermal keratoplasty) System for the treatment of low-to-moderate hyperopia. The company conducted two focus panels with
ophthalmologists in Portugal and Hawaii. Trenary discusses the comments given by the doctors, including one who tells of
experiences with a rival laser-correction procedure.
In other Sunrise Technologies news, former Vitamed Chief Operating Officer John Hendrick was appointed to the COO position
at the Fremont, CA-based company.
-----------------------------------
The 11.7 million looks like it might be getting eaten up by continuing operations.... I sure hope for SNRS sake that the have enough cash to ramp up production..
Sincerely,
Maximum Gain |
